Trials / Active Not Recruiting
Active Not RecruitingNCT06662383
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Retatrutide | Administered SC |
| DRUG | Tirzepatide | Administered SC |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2024-10-28
- Last updated
- 2026-04-13
Locations
65 sites across 5 countries: United States, Argentina, Germany, Poland, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06662383. Inclusion in this directory is not an endorsement.